Tuesday , September 21 2021

Oral medicine intended to prevent transmission of SARS-CoV-2 – treatment practice

Molnupiravir is said to completely block SARS-CoV-2 infection

There have been a number of positive reports in the last few days about new coronary vaccines to be available soon. An American research team is now reporting another success in fighting the coronavirus pandemic: Apparently the team has developed an antiviral drug that completely blocks the transmission of the SARS-KOV-2 coronavirus within 24 hours.

Researchers at Georgia State University in Atlanta, USA, report a major breakthrough in research into drugs for coronaviruses. The oral drug MK-4482 / EIDD-2801, also called molnupiravir, should completely block the transmission of SARS-CoV-2 within 24 days. The results of the study were presented in the renowned journal “Microbiology of Nature”.

Originally developed against influenza viruses

The working group led by Professor Dr. Richard Plumper actually wanted to develop an antiviral drug for seasonal flu. Due to the severity of the global coronavirus pandemic, the team changed the target of the active ingredient targeting the SARS-KOV-2 coronavirus – with success!

A real “game changer”

“This is the first evidence of an orally available drug that rapidly blocks the transmission of SARS-KOV-2,” Plumper said. Molnupiravir can change the course of the pandemic, says the professor proudly. Discontinuation of local transmission of SARS-CoV-2 is of paramount importance for the management of the COVID-19 pandemic.

The three benefits of molnupiravir

According to the research team, the drug is said to have threefold benefits. On the one hand, the active ingredient can inhibit the progression of serious diseases. On the other hand, shorten the phase of infection, and thus the quarantine time. In addition, molnupiravir can be used to break infection chains in local epidemics.

Broad-spectrum activity against respiratory RNA viruses

“We discovered early on that MK-4482 / EIDD-2801 has a wide range of activity against respiratory RNA viruses and that treating infected animals with the drug reduces the amount of virus particles excreted in several orders of magnitude, dramatically reducing transmission.” explains the head of research. These properties make molnupiravir a potent candidate for pharmacological control of COVID-19.

Ferrets simulate spread in young adults

The drug has been successfully tested on ferrets. “We believe that ferrets are a relevant model of transmission because they spread SARS-CoV-2 easily, but mostly do not develop serious disease,” he added. Robert Cox from the research team. This is similar to the spread of SARS-CoV-2 in young adults.

Incredible success

Researchers housed infected ferrets with uninfected animals in the same cage. Uninfected animals have previously received the active ingredient MK-4482 / EIDD-2801. “No contact was contagious,” said Josef Wolf, a doctoral student in the working group. In contrast, all animals in the placebo group became infected.

Tests on humans are still pending

If molnupiravir works the same way in humans as in ferrets, KOVID-19 sufferers will no longer be infectious within 24 hours of ingestion. This should now be tested in the clinical phase II / III study.

There is no information on side effects and duration of action

When taking medication, side effects, duration of action and length of treatment are of particular interest. Because the drug has so far only been tested on animals such as ferrets and mice, there is still no reliable information about this. (bb)

Information about the author and the source

This text complies with the requirements of specialist medical literature, medical guidelines and current studies and is reviewed by medical professionals.


Diploma-Editor (PH) Volker Blasek


  • Cox, RM, Wolf, JD & Plumper, RK Therapeutically administered analog ribonucleoside MK-4482 / EIDD-2801 blocks the transmission of SARS-CoV-2 into ferrets. Nat Microbiol (2020)., Doi.org
  • Georgia State University: Oral Drug Blocks Transmission of SARS-KOV-2, Georgia State Biomedical Science Researchers Reveal

Important note:
This article is for general guidance only and should not be used for self-diagnosis or self-treatment. He can not replace a visit to the doctor.

Source link